Sanggenol L Alleviates Inflammation and Ankles Joint Destruction through the Suppression of the P13K/AKT Pathway in Arthritis Prompted by Type II Collagen in Experimental Rats

. Rheumatoid arthritis (RA) is an autoimmune ailment with joint impairment and bone erosion. Hence, novel treatment approaches for RA are essential. In this current work, we assessed the anti-inflam-matory and anti-arthritic potential of Sanggenol (SGL) on collagen-induced arthritis (CIA) for the first time. The rats were arbitrarily segregated into four sets: Normal, CIA, and CIA + SGL (25 and 50 mg/kg BW). The hematological, biochemical markers, cytokines, inflammatory enzymes, histopathology of ankle joint, and western blot were explored. Hematological alterations, inflammatory enzymes, cytokines, histopathological variations, and joint inflammation were attenuated by SGL in a dosage-dependent manner. The P13K/AKT proteins level, ceruloplasmin, rheumatoid factor, and C-reactive protein in RA were relapsed by SGL. The an-ti-rheumatic action of SGL was associated with the attenuation of the P13K/AKT signaling, which suppresses cytokine production and inflammation, which reduces cartilage damage. These findings mention that SGL is unveiled as a powerful therapeutic alternative for RA remedy.